Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
Rolfo C, Rolfo C, Passiglia F, Russo A, Pauwels P.
Expert Opin Ther Targets · editorial · DOI 10.1517/14728222.2014.936383 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ceritinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
11 träffarCeritinib: first global approval.
Dhillon S, Clark M.
Drugs · review; journal article · DOI 10.1007/s40265-014-0251-3ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G, Seto T.
Clin Lung Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.cllc.2014.05.001Second-generation ALK inhibitors: filling the non "MET" gap.
Ramalingam SS, Khuri FR.
Cancer Discov · research-article; journal article · DOI 10.1158/2159-8290.cd-14-0410Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT, Engelman JA.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1404894Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shen L, Ji HF.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1404894Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Vansteenkiste JF.
Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.14.94Ceritinib gains FDA approval for lung cancer.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2014-074Approval after phase I: ceritinib runs the three-minute mile.
Chabner BA.
Oncologist · editorial · DOI 10.1634/theoncologist.2014-0143The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.
Cancer Discov · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/2159-8290.cd-13-0846Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA.
N Engl J Med · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1311107